Skip to main content

Advertisement

Table 2 Relationships between microvessel invasion and clinicopathological features in the discovery cohort

From: Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B

Variables Microvessel invasion
Yes (n = 389) No (n = 1151) P
Age, year 52.1 ± 11.6 53.3 ± 11.7 0.082
Gender, male/female 332 (85.3%)/57 (14.7%) 973 (84.5%)/178 (15.5%) 0.700
Hepatitis B history, yes/no 317 (83.6%)/62 (16.4%) 938 (83.0%)/192 (17.0%) 0.776
ALT, U/L 54.4 ± 84.7 50.7 ± 64.6 0.370
γ-GT, U/L 94.3 ± 84.9 86.9 ± 92.7 0.168
Albumin, g/L 40.9 ± 4.9 41.6 ± 4.6 0.010
Liver cirrhosis, yes/no 312 (81.0%)/73 (19.0%) 956 (84.3%)/178 (15.7%) 0.153
α-Fetoprotein (>200/≤200 ng/dL) 191 (49.1%)/198 (50.9%) 402 (34.9%)/749 (65.1%) <0.001
Tumor size, cm 6.5 ± 3.8 4.9 ± 3.3 <0.001
Tumor size (>5 cm/≤5 cm) 195 (50.1%)/194 (49.9%) 370 (32.1%)/781 (67.9%) <0.001
Tumor number, solitary/multiple 332 (85.3%)/57 (14.7%) 1009 (87.7%)/142 (12.3%) 0.239
Tumor encapsulation, complete/no 166 (42.9%)/221 (57.1%) 637 (55.4%)/512 (44.6%) <0.001
Tumor differentiation, I–II/III–IV 232 (59.9%)/155 (40.1%) 866 (76.5%)/266 (23.5%) <0.001
BCLC stage, 0/A/B 24 (6.2%)/312 (80.2%)/53 (13.6%) 170 (14.8%)/880 (76.5%)/101 (8.8%) <0.001*
  1. *, P trend. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT γ-glutamyl transpeptidase